醫管局稱若現第六波疫情 本港仍有足夠新冠口服藥
醫管局臨牀傳染病治療專責小組主席曾德賢表示,若香港出現第六波疫情,仍有足夠新冠口服藥供應。
他指,目前約2.74萬名新冠確診人士已獲處方口服藥,包括約1.77萬人服用默沙東口服藥、約9,700人服用輝瑞口服藥;另外,逾6,000名染疫院舍長者服用默沙東口服藥,適合年紀大、吞嚥能力差的院友。
醫管局日前引入首批共190多劑阿斯利康預防新冠抗體藥,他表示將會先集中使用於曾接幹細胞移植等免疫力較差的病人使用,當中以幹細胞移植的病人免疫力最弱,目前仍在商討下一批藥物的使用對象。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.